Table 1. Baseline characteristics of the contributing cohorts.
| Characteristics | FHS: Gen 2 | FHS: Gen 3 | KORA | SHIP | SUVIMAX | PREVEND |
|---|---|---|---|---|---|---|
|
| ||||||
| (N=3,103) | (N=3,757) | (N=1,786) | (N=3,125) | (N=1,518) | (N=6,487) | |
| Age, years | 59 (10) | 40 (9) | 61 (9) | 54 (15) | 51 (6) | 50 (13) |
| Female (%) | 53.2% | 53.3% | 51.3% | 51.2% | 60.4% | 50.5% |
| SBP, mmHg | 128 (19) | 117 (14) | 125 (19) | 133 (20) | 121 (12) | 130 (21) |
| DBP, mmHg | 75 (9) | 75 (10) | 76 (10) | 82 (11) | 78 (8) | 74 (10) |
| Hypertension (%) | 30.4% | 16.5% | 45.8% | 50.7% | 18.5% | 34.7% |
| Diabetes (%) | 10.9% | 3.0% | 10.4% | 10.9% | 0.3% | 3.7% |
| Prevalent CVD (%) | 10.8% | 0.9% | 3.6% | 7.9% | 0.0% | 4.0% |
| eGFR, mL/min/1.73m2 | 91 (78) | 99 (18) | 82 (18) | 85 (21) | NA | 80 (14) |
| eGFR <60 mL/min/1.73m2 (%) | 8.4% | 0.5% | 7.4% | 9.8% | NA | 6.3% |
| Aldosterone (ng/L) | 115.9 (73.9) | 128.2 (73.3) | 45.7 (31.8) | 51.5 (38.2) | 132 (89) | 132.6 (67.7) |
| PRC, ng/L | 28.5 (113.6) | NA | 23.0 (50.3) | 16.5 (35.0) | NA | 24.8 (31.8) |
| PRA, ng (angiotensin)/mL/hr | NA | 2.38 (3.56) | NA | NA | 1.97 (1.30) | NA |
FHS, Framingham Heart Study; Gen 2, Offspring cohort; Gen 3, Third Generation cohort; KORA, Cooperative Health Research in the Region of Augsburg; SHIP, Study of Health in Pomerania; SUVIMAX, Supplémentation en Vitamines et Minéraux Antioxydants; PREVEND, Prevention of REnal and Vascular ENd-stage Disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; PRA, plasma renin activity; PRC, plasma renin concentration. Data are mean (SD) or percent. NA, not available